Mirtazapine was significantly more effective than a serotonin-noradrenaline reuptake inhibitor ( venlafaxine only , two trials , n = 415 ) at two weeks ( OR 2.29 , 95 % CI 1.45 to 3.59 ) and at the end of acute-phase treatment ( OR 1.53 , 95 % CI 1.03 to 2.25).In terms of dropouts , there was no robust evidence to detect a difference between mirtazapine and other antidepressants .
Mirtazapine was more likely to cause weight gain or increased appetite and somnolence than SSRIs but less likely to cause nausea or vomiting and sexual dysfunction .
AUTHORS ' CONCLUSIONS Some statistically significant and possibly clinical ly meaningful differences between mirtazapine and other antidepressive agents were found for the acute-phase treatment of major depression .
Mirtazapine is likely to have a faster onset of action than SSRIs during the acute-phase treatment .
Dropouts occur similarly in participants treated with mirtazapine and those treated with other antidepressants , although the adverse event profile of mirtazapine is unique
BACKGROUND Mirtazapine has a unique mechanism of antidepressive action and is one of the commonly used antidepressants in clinical practice .
OBJECTIVES The aim of the present review was to assess the evidence on the efficacy and acceptability of mirtazapine compared with other antidepressive agents in the acute-phase treatment of major depression in adults .
[Comparison of reboxetine and sertraline in terms of efficacy and safety in major depressive disorder].
OBJECTIVE To compare the efficacy , safety and tolerability of reboxetine and sertraline in major depressive disorder ( MDD ) . METHOD The study subjects consisted of 41 patients who met the DSM-IV MDD diagnostic criteria . Patients were r and omly assigned to receive either reboxetine or sertraline . During the study the patients were assessed 6 times ( baseline visit = day 0 , visit 1=day 8 , visit 2=day 22 , visit 3=day 36 , visit 4=day 57 and visit 5=day 78 ) over 11 weeks . Antidepressant response was measured by the Hamilton Depression Rating Scale ( HDRS ) , Clinical Global Impressions-Severity of Illness ( CGI-SI ) and Global Impressions-Global Improvement ( CGI-GI ) . RESULTS Comparing the two groups in terms of response and remission ( HAM-D < or = 10 ) measures , the results were in favour of the reboxetine group at visits 2 , 3 and 4 . At visit 5 , the scores were similar and no statistically significant difference was found between the two groups . However , when remission was evaluated as HAM-D < or = 7 , a significant statistical difference was found in favour of the reboxetine group . Evaluating the side effects , dry mouth , sweating , palpitation , headache , hot flushing and sedation were more frequent in the reboxetine group . Only one patient , in the reboxetine group , dropped out due to a side effect ( constipation ) . CONCLUSION Higher rates of full remission achievement , which is the main target of MDD treatment , in the reboxetine group compared with the sertraline group may be due to the suppression of anxiety symptoms by the noradrenergic feature of the drug . In order to underst and the role of the noradrenergic system in treating MDD , larger patient sample s are needed . Both reboxetine and sertraline were well tolerated and effective in treating MDD
Mirtazapine was significantly more effective than a serotonin-noradrenaline reuptake inhibitor ( venlafaxine only , two trials , n = 415 ) at two weeks ( OR 2.29 , 95 % CI 1.45 to 3.59 ) and at the end of acute-phase treatment ( OR 1.53 , 95 % CI 1.03 to 2.25).In terms of dropouts , there was no robust evidence to detect a difference between mirtazapine and other antidepressants .
Mirtazapine was more likely to cause weight gain or increased appetite and somnolence than SSRIs but less likely to cause nausea or vomiting and sexual dysfunction .
AUTHORS ' CONCLUSIONS Some statistically significant and possibly clinical ly meaningful differences between mirtazapine and other antidepressive agents were found for the acute-phase treatment of major depression .
Mirtazapine is likely to have a faster onset of action than SSRIs during the acute-phase treatment .
Dropouts occur similarly in participants treated with mirtazapine and those treated with other antidepressants , although the adverse event profile of mirtazapine is unique
BACKGROUND Mirtazapine has a unique mechanism of antidepressive action and is one of the commonly used antidepressants in clinical practice .
OBJECTIVES The aim of the present review was to assess the evidence on the efficacy and acceptability of mirtazapine compared with other antidepressive agents in the acute-phase treatment of major depression in adults .